Bioenergetic Alterations After Exenatide Administration

Phase 4

Completed

Brief Summary: The purpose of this study is to find out how exenatide causes weight loss. Specifically, the study is assessing how exenatide may change how people take in energy (energy intake), as well as how it may effect how people use energy (energy expenditure).

Detailed Description: The bioenergetics study is looking at how and why the diabetes drug exenatide causes people to lose weight.Bioenergetics is the study of how your body burns calories.

Adults 18-65 who do not have diabetes and have a body mass index (BMI) between 30 and 40 may be eligible. Women who could get pregnant must be on birth control during the study and women who are pregnant cannot participate in the study.

Subjects will take exenatide for 12 weeks. There are 6 study visits in the Univ. Wisconsin Hospital General Clinical Research Center. Visits range from 1 to 6 hours and include blood and urine tests, resting metabolic rate testing over a four hour period, physical exam, ECG, and a be bone mineral density testing at another clinic during 2 clinic visits of the study.

All study procedures and testing are free of charge.

Recruitment & Eligibility

Inclusion Criteria

18-65 years of age
BMI between 30 and 40 kg/m2
Women with a negative pregnancy test at baseline, who are sterile, using contraceptives or in a committed relationship with someone who is sterile or using contraception
Absence of weight change greater than 3 kg in the previous 6 months

Exclusion Criteria

Women who are pregnant or lactating
Current or recent (6 months) enrollment in a commercial or self prescribed weight loss or exercise program
Use of weight loss medication
A history of metabolic disease i.e. renal, endocrine, hepatic or gastrointestinal disease that would impact the outcome of the study
Presence of medical conditions that are known to affect energy expenditure (i.e. hyperthyroidism, rheumatoid arthritis, AIDS among others)
History of hypoglycemia
A history of psychiatric or eating disorder
Abnormal EKG
Previous history of pancreatitis
Previous history of gastroparesis or GI motility disorder
Use of medications that can affect GI motility
History of organ transplantation
Other comorbid conditions which may preclude the subject's ability to complete the study
Use of a carbonic anhydrase inhibitor such as acetazolamide

Arm && Interventions

Group	Intervention	Description
Exenatide	Exenatide	Exenatide. Dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks Each subject serves as their own control for outcome measures taken before and during drug treatment.

Primary Outcome Measures

Name	Time	Method
Change in Energy Intake Measured Before Treatment and at the End of Treatment.	3 months	Energy intake is as calculated from energy expenditure as measured by doubly labeled water and change in body energy stores before and at the end of treatment. Units are kcal/d.

Secondary Outcome Measures